Sanofi-Aventis Sa (SNY) 50.64 $SNY
Drug Spending Is Soaring: 3 Takeaways You Can't Miss
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 21, 10:02AM CDT
Spending on hepatitis C drugs saw a jaw-dropping 743% bump in 2014. Tune in to learn what that means -- and what it doesn't -- for drug makers Gilead Sciences and AbbVie , the two major players in the hepatitis C field. The Express Scripts ...
JNJ: 102.40 (+0.71), ESRX: 85.38 (+1.43), GILD: 102.29 (+0.85), AMGN: 170.10 (+0.99), ABBV: 60.40 (-0.79), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 4:25PM CDT
Amicus Therapeutics, Inc. (FOLD) announced that it recently met with regulatory authorities in Europe and the U.S. in order to discuss the approval pathways for pipeline candidate - oral small molecule pharmacological chaperone migalastat HCl.
ANIP: 65.98 (-1.52), HZNP: 22.77 (-0.30), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 3:38PM CDT
Sanofi (SNY) announced that it has inked a multi-component strategic agreement with Evotec for the next five years.
CYTK: 7.76 (-0.19), ACOR: 34.74 (-0.39), SNY: 50.64 (+1.17), AFFX: 12.87 (-0.07)
Sanofi inks long-term drug discovery deal with Evotec
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 6:32AM CDT
SNY: 50.64 (+1.17)
The Market Has Got It Wrong - Cramer's Mad Money (3/19/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Mar 20, 6:29AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, March 19. Cramer said that the market has got it all wrong. As the indexes declined on Thursday, Cramer was shocked to realize that investors are fretting over...
SBUX: 97.46 (-0.30), HD: 117.49 (+2.33), ESPR: 112.33 (+2.19), JAH: 53.76 (+0.56), PFE: 34.25 (+0.10), RHT: 69.50 (+0.32), MCD: 97.05 (+1.07), AMGN: 170.10 (+0.99), PAH: 26.36 (+0.26), PAY: 36.08 (+0.60), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Thu Mar 19, 10:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the orphan drugmaker Amicus Therapeutics ...
SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Up As FDA, EU Green-light Quick Drug Filings
at Investor's Business Daily - Thu Mar 19, 10:03AM CDT
Small biotech Amicus Therapeutics (FOLD) jumped more than 30% Thursday after the company said it would file for accelerated approval of its lead drug candidate after positive meetings with the FDA and EU authorities. Amicus' drug migalastat would be...
INSM: 21.80 (-0.20), SRPT: 13.16 (-0.76), SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
5 Breakout Stocks to Trade for Gains After the Fed's Bombshell
at The Street - Thu Mar 19, 8:03AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
SAN: 7.28 (+0.41), UN: 43.00 (+0.69), SNY: 50.64 (+1.17), GOOG: 560.36 (+2.37), NVS: 101.68 (+1.81)
Amicus up 20% premarket on accelerated timelines for Europe and U.S. applications for migalastat
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 6:41AM CDT
SHPG: 253.64 (+3.07), PLX: 1.76 (-0.03), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Accelerates Approval Filing Plans for Rare Disease Drug
at The Street - Thu Mar 19, 6:41AM CDT
Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.
SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)
PR Newswire - Thu Mar 19, 6:00AM CDT
Sanofi announced today top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17)
Investors Relieved? Akorn Stock Retakes 50-Day Line
at Investor's Business Daily - Wed Mar 18, 2:45PM CDT
Akorn (AKRX) shares made big gains in the stock market today. The drugmaker had to restate its Q2 and Q3 2014 financial statements because of an error that led to an overstatement of revenue and earnings in Q2. But investors seem to be relieved by...
ESPR: 112.33 (+2.19), RXDX: 9.03 (+0.33), AKRX: 49.03 (-0.41), AMGN: 170.10 (+0.99), TEVA: 62.10 (+0.55), SNY: 50.64 (+1.17), NKTR: 12.02 (+0.13), REGN: 488.87 (+2.85)
Regeneron Hits a 52-Week High on Positive Praluent Data
Drug Spending Is Soaring: 3 Takeaways You Can't Miss
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 21, 10:02AM CDT
Spending on hepatitis C drugs saw a jaw-dropping 743% bump in 2014. Tune in to learn what that means -- and what it doesn't -- for drug makers Gilead Sciences and AbbVie , the two major players in the hepatitis C field. The Express Scripts ...
JNJ: 102.40 (+0.71), ESRX: 85.38 (+1.43), GILD: 102.29 (+0.85), AMGN: 170.10 (+0.99), ABBV: 60.40 (-0.79), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 4:25PM CDT
Amicus Therapeutics, Inc. (FOLD) announced that it recently met with regulatory authorities in Europe and the U.S. in order to discuss the approval pathways for pipeline candidate - oral small molecule pharmacological chaperone migalastat HCl.
ANIP: 65.98 (-1.52), HZNP: 22.77 (-0.30), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 3:38PM CDT
Sanofi (SNY) announced that it has inked a multi-component strategic agreement with Evotec for the next five years.
CYTK: 7.76 (-0.19), ACOR: 34.74 (-0.39), SNY: 50.64 (+1.17), AFFX: 12.87 (-0.07)
Sanofi inks long-term drug discovery deal with Evotec
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 6:32AM CDT
SNY: 50.64 (+1.17)
The Market Has Got It Wrong - Cramer's Mad Money (3/19/15)
SA Editor Mohit Manghnani - Seeking Alpha - Fri Mar 20, 6:29AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday, March 19. Cramer said that the market has got it all wrong. As the indexes declined on Thursday, Cramer was shocked to realize that investors are fretting over...
SBUX: 97.46 (-0.30), HD: 117.49 (+2.33), ESPR: 112.33 (+2.19), JAH: 53.76 (+0.56), PFE: 34.25 (+0.10), RHT: 69.50 (+0.32), MCD: 97.05 (+1.07), AMGN: 170.10 (+0.99), PAH: 26.36 (+0.26), PAY: 36.08 (+0.60), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Why Amicus Therapeutics, Inc. Stock Is Soaring Today
George Budwell, The Motley Fool - Motley Fool - Thu Mar 19, 10:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the orphan drugmaker Amicus Therapeutics ...
SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Up As FDA, EU Green-light Quick Drug Filings
at Investor's Business Daily - Thu Mar 19, 10:03AM CDT
Small biotech Amicus Therapeutics (FOLD) jumped more than 30% Thursday after the company said it would file for accelerated approval of its lead drug candidate after positive meetings with the FDA and EU authorities. Amicus' drug migalastat would be...
INSM: 21.80 (-0.20), SRPT: 13.16 (-0.76), SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
5 Breakout Stocks to Trade for Gains After the Fed's Bombshell
at The Street - Thu Mar 19, 8:03AM CDT
Here's a technical look at how to trade some of the biggest stocks on Wall Street.
SAN: 7.28 (+0.41), UN: 43.00 (+0.69), SNY: 50.64 (+1.17), GOOG: 560.36 (+2.37), NVS: 101.68 (+1.81)
Amicus up 20% premarket on accelerated timelines for Europe and U.S. applications for migalastat
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 6:41AM CDT
SHPG: 253.64 (+3.07), PLX: 1.76 (-0.03), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Amicus Accelerates Approval Filing Plans for Rare Disease Drug
at The Street - Thu Mar 19, 6:41AM CDT
Amicus will seek accelerated approval in the U.S. for its Fabry disease therapy in the second half of the year -- sooner than many investors expected.
SHPG: 253.64 (+3.07), SNY: 50.64 (+1.17), FOLD: 11.61 (-0.85)
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)
PR Newswire - Thu Mar 19, 6:00AM CDT
Sanofi announced today top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk population of adults with type 2 diabetes evaluating cardiovascular safety. The study showed that lixisenatide was non-inferior, although not superior, to placebo for cardiovascular safety.
SAN: 7.28 (+0.41), SNY: 50.64 (+1.17)
Investors Relieved? Akorn Stock Retakes 50-Day Line
at Investor's Business Daily - Wed Mar 18, 2:45PM CDT
Akorn (AKRX) shares made big gains in the stock market today. The drugmaker had to restate its Q2 and Q3 2014 financial statements because of an error that led to an overstatement of revenue and earnings in Q2. But investors seem to be relieved by...
ESPR: 112.33 (+2.19), RXDX: 9.03 (+0.33), AKRX: 49.03 (-0.41), AMGN: 170.10 (+0.99), TEVA: 62.10 (+0.55), SNY: 50.64 (+1.17), NKTR: 12.02 (+0.13), REGN: 488.87 (+2.85)
Regeneron Hits a 52-Week High on Positive Praluent Data
